Based in Boston, MA, STRM.BIO (“storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.

Biotechnology

STRM.BIO

Jonathan Thon

Dawn Bell

Laura Goldberg

Sadettin Ozturk

Robert Hughes

Eric Crombez

David Raiser

The Research and Development team at STRM.BIO is dedicated to advancing the science of gene therapy through the innovative use of extracellular vesicles (EVs) as delivery mechanisms. This multidisciplinary team conducts cutting-edge research to optimize EV production, enhance targeting capabilities, and evaluate therapeutic efficacy, ultimately aiming to develop new treatments for rare diseases. Collaborating closely with clinical partners, the R&D team strives to translate their groundbreaking findings into viable therapies that can improve patient outcomes globally.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at STRM.BIO

Leadership Team